Immune checkpoint inhibitors (ICIs) against cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4) and programmed cell death 1 (PD‐1) reactivate immune cells and have shown promising anti-tumor responses in a subset of advanced melanoma patients [1]. This evidence concerns the gene PDCD1 and neoplasm.